

Revance Therapeutics, Inc.  
Form 8-K  
June 13, 2016

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**  
**WASHINGTON, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d)**

**of the Securities Exchange Act of 1934**

**Date of Report (Date of earliest event reported): June 13, 2016**

**REVANCE THERAPEUTICS, INC.**

**(Exact name of registrant as specified in its charter)**

**DELAWARE**  
**(State of**

**incorporation)**

**001-36297**  
**(Commission**

**File No.)**  
**Revance Therapeutics, Inc.**

**75-0551645**  
**(IRS Employer**

**Identification No.)**

Edgar Filing: Revance Therapeutics, Inc. - Form 8-K

**7555 Gateway Boulevard**

**Newark, California 94560**

**(Address of principal executive offices and zip code)**

**Registrant's telephone number, including area code: (510) 742-3400**

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- .. Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- .. Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- .. Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- .. Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

**ITEM 8.01 OTHER EVENTS**

On June 13, 2016, Revance Therapeutics, Inc. issued a press release announcing results from its REALISE 1 Phase 3 trial of DaxibotulinumtoxinA Topical Gel. During a conference call and webcast scheduled to be held at 4:30 p.m. Eastern Daylight Time on June 13, 2016, Revance management will discuss the results from the study. A copy of the press release is filed as Exhibit 99.1 hereto and is incorporated by reference herein.

**ITEM 9.01 FINANCIAL STATEMENTS AND EXHIBITS**

**(d) Exhibits.**

<b>Number</b>	<b>Description</b>
99.1	Press Release dated June 13, 2016.

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: June 13, 2016

Revance Therapeutics, Inc.

By: /s/ Lauren P. Silvernail

Lauren P. Silvernail

Chief Financial Officer and Chief Business Officer

**EXHIBIT INDEX**

<b>Number</b>	<b>Description</b>
99.1	Press Release dated June 13, 2016.